Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Biomarker-based Exclusion of VAP for Improved Antibiotic Stewardship (VAPRapid-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01972425
Recruitment Status : Completed
First Posted : October 30, 2013
Last Update Posted : March 28, 2017
Sponsor:
Collaborator:
Wellcome Trust
Information provided by (Responsible Party):
Newcastle-upon-Tyne Hospitals NHS Trust

Brief Summary:

Critically ill patients whose lungs are supported by breathing machines (ventilators) commonly develop a new lung infection, called ventilator-associated pneumonia (VAP). Because VAP is often fatal, antibiotics are administered whenever it is suspected. However VAP is hard to distinguish from several non-infective lung conditions and most patients with suspected VAP do not have pneumonia. Therefore many patients receive unnecessary antibiotics for several days, promoting emergence of 'superbugs'. Laboratory test results for diagnosing VAP typically only reach the doctors after 3 days.

A simple test rapidly and confidently excluding VAP should improve patient care, reduce unnecessary antibiotics and decrease costs. We recently showed that low levels of specific proteins in fluid from the lungs of patients with suspected VAP effectively excluded VAP, using a test that may yield results within 6 hours. The test used is an extension of existing technology produced by our commercial partner Becton Dickinson (BD) Biosciences.

Our previous findings were derived from a single hospital's intensive care unit. We have recently confirmed this finding across many intensive care units, which will help show that the test can be used in 'real life'. The aim of this study is to take the new test to the next step and determine whether it can improve the care of patients by reducing the amount of unnecessary antibiotics prescribed. This will be done using a 'randomised controlled trial', the best tool for scientifically testing a new diagnostic test. To do this we shall identify patients with suspected VAP, all of whom will have a lung sample - half of the patients will receive 'usual care' for suspected VAP, the other half will have the new test performed on their lung fluid. If the new test suggests no lung infection, the doctors will be asked to consider not giving antibiotics. We shall test how much antibiotic is given to each group.


Condition or disease Intervention/treatment Phase
Ventilator-associated Pneumonia Other: Biomarker-based diagnostic Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 211 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Official Title: A Randomised Controlled Trial of Biomarker-based Exclusion of VAP to Improve Antibiotic Stewardship
Actual Study Start Date : October 2013
Actual Primary Completion Date : September 2016
Actual Study Completion Date : November 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Biomarker-based diagnostic
Analyse sample on arrival
Other: Biomarker-based diagnostic
The intervention will be a biomarker-based diagnostic test for the exclusion of VAP

No Intervention: Routine use of antibiotics
Do not analyse the sample on arrival



Primary Outcome Measures :
  1. Antibiotic free days (AFD) [ Time Frame: 7 days ]
    The frequency distribution of antibiotic-free days (AFD) in the 7 days following BAL



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria are based on those for adults fulfilling criteria for suspected VAP:

  • Age ≥18 years
  • Mechanically ventilated for ≥ 48hrs
  • 2 or more of:
  • Temperature <35ºC or >38ºC
  • White cell count <4x109/L or >11x109/L
  • Purulent tracheal secretions
  • New or worsening CXR or CT scan changes
  • The patient is considered suitable for early discontinuation of antibiotics

Exclusion criteria are based on features considered to predict poor tolerance of BAL and adapted from our previous studies:

  • PaO2<8kPa on FiO2>0.7
  • Positive end-expiratory pressure >15cmH2O
  • Peak airway pressure >35 cmH2O
  • Heart rate >140 bpm
  • Mean arterial pressure <65mmHg
  • Bleeding diathesis (including platelet count <20x109 per litre of blood or international normalised ratio (INR) >3)
  • Poorly controlled intracranial pressure (>20mmHg)
  • ICU consultant deems procedure not to be safe
  • Previous BAL as part of this study
  • Consent declined

Patients who are enrolled in observational studies will be eligible for co-enrolment. Co-enrolment with interventional studies will be possible following consideration of any scientific or statistical interaction, in accordance with current UK critical care research forum (UKCCRF) recommendations (see appendix). Until co-enrolment is considered appropriate for a particular study, patients enrolled in an interventional trial will not be included.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01972425


Locations
Show Show 19 study locations
Sponsors and Collaborators
Newcastle-upon-Tyne Hospitals NHS Trust
Wellcome Trust
Investigators
Layout table for investigator information
Principal Investigator: John Simpson Newcastle University
Study Data/Documents: Study Protocol  This link exits the ClinicalTrials.gov site

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Newcastle-upon-Tyne Hospitals NHS Trust
ClinicalTrials.gov Identifier: NCT01972425    
Other Study ID Numbers: NUTH6293
65937227 ( Registry Identifier: ISRCTN )
First Posted: October 30, 2013    Key Record Dates
Last Update Posted: March 28, 2017
Last Verified: March 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Pneumonia, Ventilator-Associated
Pneumonia
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Cross Infection
Infection